In the world of health and medicine, it's not uncommon for treatments to gain traction based on celebrity endorsements or sensational headlines. But what happens when a treatment gains popularity without strong scientific backing? This is the case with leucovorin, an existing medication that has been touted as a potential breakthrough for autism spectrum disorder (ASD).
The story begins with a September 2025 announcement by President Donald Trump and Robert F. Kennedy Jr., claiming a link between acetaminophen (Tylenol) and autism. While this claim was widely disputed by experts, it inadvertently drew attention to leucovorin, a form of folate (B9) that has been traditionally used to offset side effects of cancer treatments and to treat cerebral folate deficiency. The announcement suggested that leucovorin could be an exciting therapy for autism, despite limited evidence.
The researchers at the University of California, San Diego, noticed a significant increase in the prescription rate of leucovorin among children with autism following the announcement. This 'Trump bump' was further fueled by a Fox News report in February 2025, which detailed several families' experiences with the drug. The report highlighted improvements in speech deficits, which, combined with the Trump endorsement, led to a surge in leucovorin prescriptions.
However, the scientific community has been cautious about leucovorin's effectiveness for autism. The largest trial of leucovorin supplements in children with autism was retracted in January due to data errors and concerns. The Food and Drug Administration (FDA) has also been hesitant to endorse leucovorin for autism, citing a lack of strong evidence.
So, what does this mean for families and children with ASD? The study by Rothman and his team doesn't aim to provide a definitive answer, but it does highlight the importance of rigorous data. With the increase in leucovorin prescriptions, there's a growing need for long-term outcome studies to assess the drug's effectiveness and safety. This is especially crucial given the limited evidence supporting leucovorin for autism.
In my opinion, the story of leucovorin and autism is a cautionary tale about the power of celebrity endorsements and the need for scientific rigor. While it's understandable that families are eager for new treatments, it's essential to approach such claims with a critical eye. The scientific community must continue to generate rigorous data to help families and clinicians make informed decisions. Only then can we ensure that treatments are based on solid evidence, not sensational headlines.
